Centre for Congenital Heart Diseases-Paediatric Cardiology, Beatrix Children's Hospital, University Medical Centre Groningen, University of Groningen, Netherlands.
Lancet. 2012 Feb 11;379(9815):537-46. doi: 10.1016/S0140-6736(11)61621-8. Epub 2012 Jan 11.
Paediatric pulmonary hypertension, is an important cause of morbidity and mortality, and is insufficiently characterised in children. The Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension (TOPP) registry is a global, prospective study designed to provide information about demographics, treatment, and outcomes in paediatric pulmonary hypertension.
Consecutive patients aged 18 years or younger at diagnosis with pulmonary hypertension and increased pulmonary vascular resistance were enrolled in TOPP at 31 centres in 19 countries from Jan 31, 2008, to Feb 15, 2010. Patient and disease characteristics, including age at diagnosis and at enrolment, sex, ethnicity, presenting symptoms, pulmonary hypertension classification, comorbid disorders, medical and family history, haemodynamic indices, and functional class were recorded. Follow-up was decided by the patients' physicians according to the individual's health-care needs.
362 of 456 consecutive patients had confirmed pulmonary hypertension (defined as mean pulmonary artery pressure ≥25 mm Hg, pulmonary capillary wedge pressure ≤12 mm Hg, and pulmonary vascular resistance index ≥3 WU/m(-2)). 317 (88%) patients had pulmonary arterial hypertension (PAH), which was idiopathic [IPAH] or familial [FPAH] in 182 (57%), and associated with other disorders in 135 (43%), of which 115 (85%) cases were associated with congenital heart disease. 42 patients (12%) had pulmonary hypertension associated with respiratory disease or hypoxaemia, with bronchopulmonary dysplasia most frequent. Finally, only three patients had either chronic thromboembolic pulmonary hypertension or miscellaneous causes of pulmonary hypertension. Chromosomal anomalies, mainly trisomy 21, were reported in 47 (13%) of patients with confirmed disease. Median age at diagnosis was 7 years (IQR 3-12); 59% (268 of 456) were female. Although dyspnoea and fatigue were the most frequent symptoms, syncope occurred in 31% (57 of 182) of patients with IPAH or FPAH and in 18% (eight of 45) of those with repaired congenital heart disease; no children with unrepaired congenital systemic-to-pulmonary shunts had syncope. Despite severe pulmonary hypertension, functional class was I or II in 230 of 362 (64%) patients, which is consistent with preserved right-heart function.
TOPP identifies important clinical features specific to the care of paediatric pulmonary hypertension, which draw attention to the need for paediatric data rather than extrapolation from adult studies.
Actelion Pharmaceuticals.
儿科肺动脉高压是发病率和死亡率的一个重要原因,但其在儿童中的特征描述不足。Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension(TOPP)登记处是一项全球性、前瞻性研究,旨在提供儿科肺动脉高压患者的人口统计学、治疗和结局信息。
2008 年 1 月 31 日至 2010 年 2 月 15 日,在 19 个国家的 31 个中心,对诊断为肺动脉高压和肺血管阻力增加的 18 岁或以下的连续患者进行了 TOPP 登记。记录了患者和疾病特征,包括诊断和登记时的年龄、性别、种族、首发症状、肺动脉高压分类、并存疾病、医疗和家族史、血流动力学指标和功能状态。根据患者的个体医疗需求,由患者的医生决定随访。
在 456 例连续患者中,有 362 例(88%)患有明确的肺动脉高压(定义为平均肺动脉压≥25mmHg,肺毛细血管楔压≤12mmHg,肺血管阻力指数≥3WU/m2)。317 例(88%)患者患有肺动脉高压(PAH),其中特发性肺动脉高压(IPAH)或家族性肺动脉高压(FPAH)182 例(57%),与其他疾病相关 135 例(43%),其中 115 例(85%)与先天性心脏病相关。42 例(12%)患有与呼吸疾病或低氧血症相关的肺动脉高压,其中支气管肺发育不良最常见。最后,只有 3 例患者患有慢性血栓栓塞性肺动脉高压或其他原因的肺动脉高压。在确诊的 47 例(13%)患者中报告了染色体异常,主要为 21 三体。诊断时的中位年龄为 7 岁(IQR 3-12);59%(268/456)为女性。虽然呼吸困难和疲劳是最常见的症状,但在 182 例 IPAH 或 FPAH 患者中有 31%(57 例)和在 45 例(18%)已修复的先天性心脏病患者中出现晕厥;无未修复的先天性体肺分流术患儿出现晕厥。尽管存在严重的肺动脉高压,但在 362 例患者中有 230 例(64%)的功能状态为 I 级或 II 级,这与右心功能保存一致。
TOPP 确定了儿科肺动脉高压治疗的重要临床特征,这些特征引起了人们对儿科数据的关注,而不是从成人研究中推断。
Actelion 制药公司。